17 Molto L, Alvarez Mon M, Carballido J, et al. Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation. Br J Cancer, 1994, 70∶1247-1251.
18 Portillo J, Martin B, Hernandez R, et al. Results at 43 months' follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder. Urology,1997,49∶187-190.
19 Sarosdy MF, Lowe BA, Schellhammer PF, et al. Oral bropirimine immunotherapy of carcinoma in situ of the bladder: Results of a phase Ⅱ trial. Urology, 1996, 48∶21-27.
20 Ikemoto S, Kamizuru M, Wada S, et al. Changes in lymphocyte subsets following administration of interleukin 2 and cyclophosphamide in mice with transitional cell carcinoma. Oncol Res, 1997, 9∶71-75.
21 Nouri AM, Lowdell M, Entazami Z, et al. Comparison of immunological changes between subcutaneous and intravenous route of administration of IL-2 in cancer patients. Urol Int, 1996, 56∶1-5.
22 Glazer DB, Bahnson RR, Mc Leod DG, et al. Intravesical recombinant tumor necrosis factor in the treatment of superficial bladder cancer: An eastern cooperative oncology group study. J Urol, 1995, 154∶66.
23 Aso Y, Akaza H, Kotake T, et al. Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial.the BLP study group. Eur Urol, 1995, 27∶104-109.
24 Chin JL, Kadhim SA, Batislam E, et al. Mycobacterium cell wall: an alternative to intravesical bacillus Calmette-Guerin (BCG) therapy in orthotopic murine bladder cancer. J Urol, 1996 156∶1189-1193.
25 De Reijke TM, de Boer EC, Schamhart DH, et al. Immunostimulation in the urinary bladder by local application of Nocardia rubra cell wall skeleton preparation (Rubratin）for superficial bladder cancer immunotherapy--a phase I/II study. Urol Res, 1997, 25∶117-120.
26 陈仕平，许恩赐，林震，等.N-CWS膀胱灌注预防膀胱癌术后复发的远期疗效观察.中华泌尿外科杂志，1996，17∶412-414.
27 Raica M. Effects of intravesical Corynebacterium parvum on recurrences of superficial tumors of the urinary bladder. Anticancer Drugs, 1992，3∶39-42.
28 Jurincic-Winkler CD, Gallati H, Alvarez Mon M, et al. Urinary interleukin-1 alpha levels are increased by intravesical instillation with keyhole limpet hemocyanin in patients with superficial transitional cell carcinoma of the bladder. Eur Urol, 1995, 28∶334-339.
29 Jurincic Winkler C, Metz KA, Beuth J, et al. Immunohistological findings in patients with superficial bladder carcinoma after intravesical instillation of keyhole limpet haemocyanin. Br J Urol, 1995 76∶702-707.
30 Jurincic-Winkler CD, von der Kammer H, Beuth J, et al. Antibody response to keyhole limpet hemocyanin (KLH) treatment in patients with superficial bladder carcinoma. Anticancer Res， 1996, 16(4A)∶2105-2110.
31 Heimbrook DC, Stirdivant SM, Ahern JD, et al. Transforming growth factor alpha-pseudomonas exotoxin fusion protein prolongs survival of nude mice bearing tumor xenografts. Proc Natl Acad Sci USA, 1994, 87∶4697.
32 Theuer CP, FitzGerald DJ, Pastan I, et al. A recombinant form of pseudomonas exotoxin a containing transforming growth factor alpha near its carboxyl terminus for the treatment of bladder cancer. J Urol, 1993，149∶1626-1632.
33 Riggs DR, DeHaven JI. Allium sativum (garlic) treatmennt for murine transitional cell carcinoma. Cancer, 1997,79∶1987-1994.
34 孙世平,谢蜀生,俞莉章,等.免疫毒素导向治疗膀胱癌的实验与临床研究. 中华泌尿外科杂志,1996,17:263-266.
